Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.

MRNA joins the Nasdaq-100 after a 700% run this year

Moderna (MRNA) has been added to the Nasdaq-100 index, capping a 700% stock surge this year. That move puts the name into the benchmark that QQQ tracks, which is why the inclusion matters for flows.

The rally rests on three named catalysts: FDA approvals of updated COVID-19 vaccines, FDA approval of a flu vaccine, and promising phase 3 trial results for its cancer vaccine candidate. The cancer program is the piece the source highlights as the forward-looking story, with MRK as the named partner context for that candidate in market discussion.

The index addition is expected to broaden institutional ownership. Index inclusion typically brings mechanical demand from funds that track the benchmark, so the source's view is that the stock price could be pushed higher. That's interpretation of the source's logic rather than a guarantee: a 700% move means much of the good news may already sit in the price, and index-driven buying tends to be a one-time event rather than a lasting driver.

The source's advice to investors is to look past the index headline and focus on the cancer vaccine pipeline's future potential, since the phase 3 results are the catalyst with the longest runway.